B830-ADC

B830-ADC is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by Shanxi Naan Biotechnology for the treatment of solid tumors, including lung cancer, pancreatic cancer, and esophageal cancer. As a bispecific ADC, the molecule is engineered to bind two different tumor-associated antigens simultaneously, which is intended to enhance tumor selectivity and internalization compared to traditional monospecific ADCs. The drug is designed for intravenous administration. While the specific antigen targets, linker technology, and cytotoxic payload have not been publicly disclosed by the sponsor, the program is part of Shanxi Naan's broader focus on nanobody-based therapeutic platforms.